Clinical Trials Logo

Recurrent Endometrial Carcinoma clinical trials

View clinical trials related to Recurrent Endometrial Carcinoma.

Filter by:

NCT ID: NCT00301964 Completed - Clinical trials for Recurrent Endometrial Carcinoma

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: March 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT00096447 Completed - Clinical trials for Recurrent Endometrial Carcinoma

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: November 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

NCT ID: NCT00095979 Completed - Clinical trials for Endometrial Adenocarcinoma

Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: May 2005
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well ixabepilone works in treating patients with recurrent or persistent endometrial cancer.

NCT ID: NCT00072176 Completed - Clinical trials for Endometrial Adenocarcinoma

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back after a period of time during which the cancer could not be detected. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00031681 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

NCT ID: NCT00028535 Completed - Clinical trials for Recurrent Breast Cancer

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Start date: November 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining interleukin-12, chemotherapy, and monoclonal antibody therapy may kill more tumor cells.

NCT ID: NCT00025467 Completed - Clinical trials for Endometrial Adenocarcinoma

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy